Perceptive’s investment strategies are built upon extensive fundamental analysis and decades of experience investing in small and mid-capitalization healthcare companies. Our approach is based on an in depth scientific analysis of every step in the development pathway of a new therapeutic, device, or diagnostic. We focus on avoiding the biases that can affect investment decisions and have the ability to adapt to meet an evolving landscape.
Perceptive invests in companies that offer innovative solutions to healthcare needs.
Below is a list of selected private investments.
A clinical-stage biopharmaceutical company focused on discovering and developing targeted cancer immunotherapies. The company engineers and develops next-generation bispecific antibodies that bind with high specificity and affinity to certain cancer cells and direct the most potent cells of the human immune defense arsenal, to attack and kill cancer cells.
Bellicum's CID Technology Enhances Potential of Cellular Immunotherapy Cell signaling switches enable control over immune activity. Bellicum’s unique technology, designed to give physicians control over cells and immune activity inside the body, aims to make cell therapies safer and more effective.
A clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat life threatening ("orphan") inflammatory-fibrotic diseases with clear unmet needs.
A genetic information company making genetic testing more affordable and accessible than ever before by lowering the barriers to genetic results for clinicians and patients.
Otonomy’s mission is to develop and commercialize novel and best-in-class therapeutics to address unmet medical needs in the emerging otology market, which overcome many of the limitations of delivering drugs to the middle and inner ear.
A biopharmaceutical company focused on the discovery and development of drugs for the treatment of catastrophic diseases that are debilitating and often life-threatening, and for which there are currently limited patient options.
A private company focused on acquiring and developing disease modifying therapies for Duchenne Muscular Dystrophy through rigorous scientific analysis, efficient capital management and global collaborations.
Tivorsan Pharmaceuticals is a protein therapeutics company pioneering a unique approach to treat serious neuromuscular disorders, including Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD).
A biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. The vaccine platform allows for the design of vaccines that closely mimic the target virus. VBI has also completed proof of concept thermostability studies on a number of vaccine and biologic
A biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders utilizing the novel half-life extension technology, XTEN, in the treatment of naïve, pre-pubertal children with growth hormone deficiency (GHD).
Virobay is focused on developing protease inhibitors for the treatment of autoimmune diseases, neuropathic pain, liver diseases and cancer.